Migraine-specific Quality of Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: CGAN Japan Phase 2 Study
AHSAM 2020 - Poster session
Published on October 2, 2020 | NEW
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
- The objective of this secondary analysis was to compare galcanezumab with placebo with respect to changes in quality of life, as assessed by the Migraine- Specific Quality-of-Life Questionnaire (MSQ version 2.1), in Japanese patients with episodic migraine (EM).
- Quality of life and functioning of Japanese patients with EM were improved by 1 month after the initiation of GMB treatment, and these effects were maintained for 6 months.
- The MSQ score was improved in all 3 domains (Role Function-Restrictive [RFR], Role Function-Preventive [RFP], and Emotional Function [EF]), and the total score.
Mamoru Shibata, MD, PhD
Department of Neurology, Tokyo Dental College Ichikawa General Hospital
Ichikawa, Chiba, Japan
Mamoru Shibata is the Professor at Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan He is also a Visiting Professor of Neurology, Keio University School of Medicine. He graduated from Keio University School of Medicine in 1992. He worked on the role of autophagy in the pathogenesis of Huntington’ disease as a postdoc at Department of Cell Biology, Harvard Medical School from 2002 through 2005. After returning to Japan, he joined the faculty at Department of Neurology, Keio University School of Medicine, where he was eventually promoted to Associate Professor. He sees a lot of headache patients. He has been also engaging in basic research of migraine since 2009. He is involved in various aspects of activity of the Japanese Headache Society. He is currently serving as Chair of the Pan Asian Committee of AHS.